The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Acute kidney injury in patients treated with immune checkpoint inhibitors
Open accessAbstract
Background: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods: We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results: ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions: Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
González, E., Gutiérrez, E., Galeano, C., Chevia, C., de Sequera, P., Bernis, C., Parra, E. G., Delgado, R., Sanz, M., Ortiz, M., et al. (2008) · Kidney International · doi:10.1038/sj.ki.5002776 · Cited by 466
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070676 · Cited by 407
Self-citation
Research works printed but not linked: 26
- Manohar, 2019, Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis, Nephrol Dial Transplant, 34, 108, 10.1093/ndt/gfy105 · DOI · Paper page
- Seethapathy, 2019, The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors, CJASN, 14, 1692, 10.2215/CJN.00990119 · DOI · Paper page
- 10.1136/jitc-2019-000467 · DOI · Paper page
- 10.1016/j.ejca.2021.01.005 · DOI
- García-Carro, 2021, Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors, Nephrol Dial Transplant
- Stein C , Burtey S , Mancini J . Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant 2020. · DOI
- Hultin S , Nahar K , Menzies AM , et al . Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrol 2020;21.doi:10.1186/s12882-020-02044-9 · DOI
- Darmon M , Vincent F , Canet E . Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Rnimation Respiratoire en Onco-Hatologie. Nephrol Dial Transplant 2015. · DOI
- 10.1053/j.ackd.2013.07.004 · DOI
- 10.1053/j.ajkd.2016.02.057 · DOI · Paper page
- Oleas, 2021, Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience, Clin Kidney J, 14, 1364, 10.1093/ckj/sfaa008 · DOI
- Mamlouk O , Selamet U , Machado S , et al . Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. j. immunotherapy cancer 2019;7.doi:10.1186/s40425-018-0478-8 · DOI · Paper page
- Isik, 2021, Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events, Kidney Int Rep, 6, 1022, 10.1016/j.ekir.2021.01.013 · DOI
- Bellomo R , Ronco C , Kellum JA . Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. In: Critical Care (London, England) 2004. · DOI · Paper page
- 10.1016/j.kint.2016.04.008 · DOI · Paper page
- Seethapathy, 2020, Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors, Kidney Int Rep, 5, 1700, 10.1016/j.ekir.2020.07.011 · DOI
- 10.1038/ki.2014.74 · DOI · Paper page
- Qiu, 2018, Acid-suppressive drugs and risk of kidney disease: a systematic review and meta-analysis, J Gastroenterol Hepatol, 33, 1566, 10.1111/jgh.14157 · DOI
- 10.1002/phar.2235 · DOI
- 10.34067/KID.0000852019 · DOI
- 10.1002/cncr.27969 · DOI · Paper page
- 10.1200/JCO.2015.66.1389 · DOI · Paper page
- Gallan, 2019, Renal vasculitis and Pauci-immune glomerulonephritis associated with immune checkpoint inhibitors, Am J Kidney Dis, 74, 853, 10.1053/j.ajkd.2019.04.016 · DOI
- 10.1016/j.athoracsur.2017.12.034 · DOI
- 10.1161/CIRCULATIONAHA.119.044703 · DOI · Paper page
- 10.34067/KID.0000152019 · DOI
Cited by
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67
Self-citationMiao, J., & Herrmann, S. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad109 · Cited by 31
“It has been shown that duration of corticosteroids of 28 days or less is safe and has similar efficacious compared to longer durations for patients with ICI-AKI [8].”
BackgroundResultInfluentialSelf-citationSeethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15
Self-citation
Metadata
- Authors
- Gupta, S., Short, S. A. P., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., Glezerman, I., Motwani, S. S., Murakami, N., Wanchoo, R., Ortiz-Melo, D. I., Rashidi, A., Sprangers, B., Aggarwal, V., Malik, A. B., Loew, S., Carlos, C. A., Chang, W.-T., Beckerman, P., Mithani, Z., Shah, C. V., Renaghan, A. D., Seigneux, S. D., Campedel, L., Kitchlu, A., Shin, D. S., Rangarajan, S., Deshpande, P., Coppock, G., Eijgelsheim, M., Seethapathy, H., Lee, M. D., Strohbehn, I. A., Owen, D. H., Husain, M., Garcia-Carro, C., Bermejo, S., Lumlertgul, N., Seylanova, N., Flanders, L., Isik, B., Mamlouk, O., Lin, J. S., Garcia, P., Kaghazchi, A., Khanin, Y., Kansal, S. K., Wauters, E., Chandra, S., Schmidt-Ott, K. M., Hsu, R. K., Tio, M. C., Sarvode Mothi, S., Singh, H., Schrag, D., Jhaveri, K. D., Reynolds, K. L., Cortazar, F. B., & Leaf, D. E.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-10
- Volume
- 9
- Issue
- 10
- Pages
- e003467
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3202872245
- Cited by
- 236
- References
- 7
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-04-24)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute kidney injury in patients treated with immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1136/jitc-2021-003467
- The paper
- Gupta, S., Short, S. A. P., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., Glezerman, I., Motwani, S. S., Murakami, N., Wanchoo, R., Ortiz-Melo, D. I., Rashidi, A., Sprangers, B., Aggarwal, V., Malik, A. B., . . . Leaf, D. E. (2021). Acute kidney injury in patients treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-003467
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.